The Basics

1. What is cardiac PET?

Cardiac positron emission tomography (PET) is a non-invasive imaging test that measures blood flow to the heart muscle. Using a positron-emitting tracer, most commonly rubidium-82 and a PET (or PET/CT) scanner, it images myocardial perfusion at rest and under pharmacologic stress, and can quantify blood flow in absolute terms. ¹

2. What makes it different from a standard nuclear stress test (SPECT)?

Two advantages:

1. PET is generally more accurate, particularly in women and patients with a high BMI. ²
2. PET routinely quantifies absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR), i.e. actual numbers not just a relative perfusion map, which SPECT cannot match. The Quantitative Cardiac Imaging (QCI) Study Group rated PET the highest non-invasive modality for both absolute and relative perfusion quantification. ³

3. Does adding flow quantification make the scan longer or higher-dose?

No. Measuring MBF does not add radiation or imaging time. The flow data come from the same dynamic acquisition. ⁴

Who Benefits

4. Which patients are best suited to cardiac PET?

Current guidelines and consensus statements increasingly support PET myocardial perfusion imaging, particularly when its advantages in diagnostic accuracy, low radiation exposure and myocardial blood-flow quantification are clinically valuable.

Situations where cardiac PET offers advantages include ^5,6,7 :

• Patients with suspected or known coronary artery disease (CAD) who require myocardial perfusion imaging.
• Patients unable to exercise, for whom pharmacologic stress PET provides an effective alternative.
• Patients whose body habitus affect image quality — obesity, large breasts, breast implants, protuberant abdomen.
• Young patients, or patients likely to require repeated testing, where PET's relatively low radiation exposure is advantageous.
• Patients with suspected multivessel or microvascular diseases, where flow quantification is decisive.
• Patients with prior inconclusive or equivocal imaging.
• High-risk patients, including those with diabetes, chronic kidney disease, or known/suspected multivessel or left-main CAD, where PET's diagnostic accuracy, risk stratification and MBF quantification can be particularly valuable.

5. Why is PET especially valuable in women?

Women have a higher burden of non-obstructive and microvascular disease, which relative perfusion imaging tends to miss, and are more prone to soft-tissue attenuation artefacts on SPECT. PET's attenuation correction and flow quantification directly address both — and the measured sensitivity advantage is largest in women. ²

6. What is microvascular dysfunction, and how does PET detect it?

Coronary microvascular dysfunction (CMD) is impaired function of small coronary vessels that regulate myocardial blood flow. It can cause angina and/or ischaemia despite the absence of obstructive epicardial coronary disease, contributing to INOCA (ischaemia with non-obstructive coronary arteries). Because CMD can cause a diffuse reduction in coronary flow rather than a focal regional defect, relative perfusion imaging may appear normal. PET can detect impaired microvascular function by measuring MBF and MFR. A reduced hyperaemic/stress MBF and particularly a low MFR indicate an impaired ability of the coronary circulation to increase blood flow during vasodilator stress.

Patients at increased risk of CMD include those with hypertension, diabetes and dyslipidaemia, with CMD and microvascular angina also being more prevalent in women. ⁸

What The Results Mean

7. What is myocardial flow reserve (MFR), and why does it matter?

MFR is the ratio of stress to rest blood flow, how much the coronary circulation can increase flow on demand. It is a powerful prognostic marker: in a registry of over 7,000 patients, an MFR ≤2 was independently associated with higher all-cause mortality across the spectrum of perfusion findings, including in patients with no reversible perfusion defects. ⁹ It also helps identify which patients benefit from revascularisation. ¹⁰

8. How are PET results used to categorise risk?

By combining stress MBF and MFR, patients sort into defined risk groups from abnormal-MBF-and-abnormal-MFR (highest risk, cardiac mortality >3%/year) to normal-and-normal (lowest, <0.5%/year), with informative discordant patterns in between. ¹ In one study, flow quantification reclassified 35% of intermediate-risk patients into clearer high- or low-risk categories. ¹¹

9. Does PET reduce unnecessary downstream procedures?

Yes. Its greater accuracy reduces subsequent invasive angiography and revascularisation compared with SPECT, with total CAD management costs reduced by approximately 30% when PET MPI is used routinely. ¹²

Practical and Comparative Questions

10. What does cardiac PET involve for the patient?

A rest scan and a pharmacologic-stress scan, completed in about 30 minutes of scanner time. A vasodilator medication mimics the effect of exercise, where the tracer is given by IV and ECG electrodes are used to monitor the heart throughout. ¹³ Most patients can complete the entire visit within about an hour.

11. Why pharmacologic stress rather than exercise?

Rubidium-82 has a very short physical half-life of approximately 75 seconds, making conventional treadmill exercise impractical for PET myocardial perfusion imaging. Pharmacologic (vasodilator) stress is used instead. PET MPI is also particularly useful for patients who are unable to exercise adequately. ⁵

12. Is PET safe? What are the risks?

The imaging itself is low dose. The principal risk relates to the pharmacologic stress agent, which can rarely cause serious reactions. Testing is therefore performed only where cardiac resuscitation equipment and trained staff are available. ¹³

13. Does PET compete with coronary CT angiography (CTA)?

They answer different questions and are often complementary. Coronary CTA primarily defines coronary anatomy, whether and where coronary artery disease is present. PET assesses myocardial perfusion and function, including whether coronary disease is associated with impaired blood flow, and can quantify myocardial blood flow and flow reserve. In practice, anatomy can identify the presence and extent of disease, while functional assessment helps determine its physiological significance and can inform management and revascularisation decisions.

14. Do we need a cyclotron to offer cardiac PET?

No. Rubidium-82 is produced on-site from a generator, with no cyclotron required, which is what makes a PET cardiac service feasible for centers that already have a PET/CT scanner. ¹⁴

For The Referring Clinician

15. When should I refer a patient for cardiac PET rather than SPECT or CTA?

Consider PET:

• When you need accurate ischaemia assessment in a patient who is obese, female, or unable to exercise
• When you suspect multivessel or microvascular disease
• When prior imaging was equivocal
• When flow quantification would change management or risk assessment

Consider CTA when the question is primarily anatomical, and SPECT when a focal relative-perfusion answer suffices or exercise stress is specifically wanted.

16. What information will the report give me?

Beyond the perfusion images, a quantitative PET report provides stress and rest MBF, MFR, and a risk categorization, directly informing prognosis and management decisions, including the value of revascularisation.

References

QT Instruments supports cardiac PET programmes across Southeast Asia with clinical education, referrer engagement, and program development resources.